[18F]Fluorocholine PET/CT-guided stereotactic body radiotherapy in patients with recurrent oligometastatic prostate cancer

Francesco Pasqualetti, Marco Panichi, Martina Sollini, Aldo Sainato, Luca Galli, Riccardo Morganti, Serena Chiacchio, Andrea Marciano, Roberta Zanca, Lorenzo Mannelli, Gabriele Coraggio, Andrea Sbrana, Paola Cocuzza, Sabrina Montrone, Davide Baldaccini, Alessandra Gonnelli, Alessandro Molinari, Martina Cantarella, Valentina Mazzotti, Sergio RicciFabiola Paiar, Paola Anna Erba

Research output: Contribution to journalArticle

Abstract

Background: In the last years, functional imaging has given a significant contribution to the clinical decision-making of biochemically relapsed prostate cancer (PCa). Hereby, we present a prospective study aiming to validate the role of [18F]Fluoro-Methyl Choline ([18F]FMCH) PET/CT in the selection of PCa patients suitable for stereotactic body radiotherapy (SBRT). Methods: Patients with biochemical recurrence limited up to three lesions revealed by [18F]FMCH PET/CT were enrolled in the present study and treated with SBRT on all active lesions. Systemic therapy-free survival since the [18F]FMCH PET/CT was considered as the primary endpoint. Results: Forty-six patients were evaluated, and a total of 67 lesions were treated. After a median follow-up of 28.9 months, systemic therapy was started in 30 patients (65.2%) and median systemic therapy-free survival was 39.1 months (95% CI 6.5–68.6); 6, 12, and 24-month ratios were 93.5%, 73.9%, and 63.1%, respectively. At univariate Cox regression analysis, Delta PSA demonstrated an impact on systemic therapy-free survival (p < 0.001). Conclusions: Based on our findings, [18F]FMCH PET/CT can identify oligometastatic prostate cancer patients suitable for SBRT, resulting in a systemic therapy-free survival of 39.1 months.

Original languageEnglish
Pages (from-to)185-191
Number of pages7
JournalEuropean Journal of Nuclear Medicine and Molecular Imaging
Volume47
Issue number1
DOIs
Publication statusE-pub ahead of print - Oct 16 2019

    Fingerprint

Keywords

  • Prostate cancer
  • Stereotactic body radiotherapy
  • [F]FMCH PET/CT

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Cite this

Pasqualetti, F., Panichi, M., Sollini, M., Sainato, A., Galli, L., Morganti, R., Chiacchio, S., Marciano, A., Zanca, R., Mannelli, L., Coraggio, G., Sbrana, A., Cocuzza, P., Montrone, S., Baldaccini, D., Gonnelli, A., Molinari, A., Cantarella, M., Mazzotti, V., ... Erba, P. A. (2019). [18F]Fluorocholine PET/CT-guided stereotactic body radiotherapy in patients with recurrent oligometastatic prostate cancer. European Journal of Nuclear Medicine and Molecular Imaging, 47(1), 185-191. https://doi.org/10.1007/s00259-019-04482-6